Supernus (SUPN) Director Reports 1,000-Share Sale Executed via 10b5-1
Rhea-AI Filing Summary
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of 1,000 shares of the issuer's common stock on 08/25/2025 pursuant to a 10b5-1 trading plan adopted March 3, 2025. The filing shows a weighted average sale price of $45 (individual trades ranged $45.00–$45.01) and indicates the reporting person beneficially owned 133,232 shares after the transaction. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and was filed as a single-person report.
Positive
- Transaction executed under a documented 10b5-1 plan, indicating pre-planned trading and affirmative defense intent
- Weighted average price and execution range disclosed ($45.00–$45.01) and reporting person offers to provide detailed per-trade breakdown on request
- Filing by a single reporting person with attorney-in-fact signature, reflecting standard procedure and timely disclosure
Negative
- Director sold 1,000 shares, reducing beneficial ownership to 133,232 shares
- Sale represents insider liquidity, which some investors may view as minor negative signal despite 10b5-1 plan
Insights
TL;DR: Small, pre-planned sale by a director under a 10b5-1 plan; minimal ownership change relative to total stated holdings.
The sale of 1,000 shares against remaining beneficial ownership of 133,232 shares represents a modest reduction in holdings (under 1%). Because the transaction was executed under a documented 10b5-1 plan adopted March 3, 2025, it indicates pre-scheduled liquidity rather than an opportunistic insider trade. The filing discloses a weighted average price of $45 with a narrow execution range ($45.00–$45.01), which provides useful price transparency. Overall, this is a routine insider liquidity event with limited direct financial impact on the company.
TL;DR: Proper procedural disclosure under Rule 10b5-1; filing meets transparency expectations for director trades.
The Form 4 clearly states the use of a 10b5-1 trading plan and provides an undertaking to supply detailed per-trade pricing to the company or SEC staff if requested, which enhances disclosure quality. The report was filed by one reporting person and signed by an attorney-in-fact, consistent with common practice. The transaction size is small relative to the director's remaining stake, suggesting routine portfolio rebalancing rather than a governance red flag.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,000 | $45.00 | $45K |
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
